All filters
Slidesets
Pharmacokinetic and virological efficacy of dolutegravir (50 mg BID) containing regimen in association with rifampin in HIV-infected patients using Dried Blood Spot: ANRS-12313 NAMSAL sub-study in Cameroon- Le
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
First report of dolutegravir unbound plasma concentrations during pregnancy in HIV-positive women- Pauline Bollen
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Update on DDI guidelines of the FDA - in vitro- Xinning Yang, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Update on DDI guidelines of the FDA - in vivo- Kellie Reynolds, PharmD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
How to End the Global HCV Epidemic - the role of injectables- David Thomas, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Medication safety issues associated with currently used first-line antiretroviral regimens in Uganda- Kay Seden
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Intraindividual comparison of efavirenz, atazanavir, or ritonavir plasma pharmacokinetics before and during 21-days of vaginally administered hormone contraception- Kimberly Scarsi, PharmD, MS, FCCP
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Rifabutin (RBT) Decreases Cabotegravir (CAB) Exposure following Oral Co-administration- Patel
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Rifabutin PK and Safety among HIV/TB Coinfected Children Receiving Lopinavir- Holly Rawizza
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Clinical Pharmacology of HIV Pre-Exposure Prophylaxis (PrEP) – Where are we now?- Craig Hendrix
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics of Etravirine in HIV-positive Children Ages 1-<6 Years- Mustafa IBrahim
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Differential brain tissue penetration of antiretrovirals and fluconazole- Katelyn Pastick
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Understanding complexities of gut microbiome dysbiosis in HIV infected populations using a large cohor- Abigail Armstrong
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2017
Slidesets
Differential responses of colonic ILCs to gut commensal bacteria altered during HIV infection- Moriah Castleman, PhD
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2017
Slidesets
Milk - guiding the infant microbiome - Bruce German, PhD
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2017
Slidesets
The microbial-derived short chain fatty acid butyrate directly and differentially inhibits gut T helper cell subset activation and proliferation- Jon Kibbie
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2017
Slidesets
Opening Lecture: Brain-Gut-Microbiota interactions and intestinal health- Wendy Henderson, PhD, MSN, CRNP
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2017
Slidesets
Role of the microbiome in HIV vaccine response heterogeneity- James Kublin, MD, MPH
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2017
Slidesets
Microbial colonization of the gut and brain development in infancy- Rebecca Knickmeyer, PhD
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2017
Slidesets
Microbial dysbiosis does not alter immune activation or disease progression in SIV-infected rhesus macaques- Alexandra Ortiz
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2017
Slidesets
Plasma tryptophan-kynurenine metabolites are altered with gut microbiota dysbiosis in HIV infection and associated with progression of carotid artery atherosclerosis- Qibin Qi, PhD
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2017
Slidesets
Cervicovaginal microbial dynamics and its impact on HIV acquisition risk- Douglas Kwon, MD, PhD
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2017
Slidesets
Vaginal lactic acid inhibits production of pro-inflammatory mediators from human cervicovaginal epithelial cells associated with HIV acquisition- Gilda Tachedjian
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2017